ABSTRACT
Dendritic cells (DCs) have shown promise for use in cancer vaccine and cancer immunotherapy studies. However, we demonstrate that cancer cell lines can negatively interfere with DC generation in granulocyte-macrophage colony-stimulating factor (GM-CSF)-derived cultures, although cancer cells are able to enhance CD80 cell surface activation marker and cytokine secretion. Furthermore, in the presence of cancer cells, GM-CSF-derived DCs are unable to stimulate T-cells. Additional stimulation with toll-like receptor 4 cannot fully reverse the suppressive effect of cancer cells or supernatant. Hence, it is imperative to understand the immunosuppressive effects of cancer on DCs in order for DC-based cancer immunotherapy to be successful.
Subject(s)
Dendritic Cells/immunology , Immune Tolerance , Toll-Like Receptor 4/agonists , Animals , Cell Line, Tumor , Cell Proliferation , Dendritic Cells/drug effects , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Immunotherapy , Lipopolysaccharides/administration & dosage , Mice , Mice, Inbred BALB C , Mice, Inbred C57BLABSTRACT
Removal of dead cells in the absence of concomitant immune stimulation is essential for tissue homeostasis. We recently identified an injury-induced protein misfolding event that orchestrates the plasmin-dependent proteolytic degradation of necrotic cells. As impaired clearance of dead cells by the innate immune system predisposes to autoimmunity, we determined whether plasmin could influence endocytosis and immune cell stimulation by dendritic cells - a critical cell that links the innate and adaptive immune systems. We find that plasmin generated on the surface of necrotic cells enhances their phagocytic removal by human monocyte-derived dendritic cells. Plasmin also promoted phagocytosis of protease-resistant microparticles by diverse mouse dendritic cell sub-types both in vitro and in vivo. Together with an increased phagocytic capacity, plasmin-treated dendritic cells maintain an immature phenotype, exhibit reduced migration to lymph nodes, increase their expression/release of the immunosuppressive cytokine TGF-ß, and lose their capacity to mount an allogeneic response. Collectively, our findings support a novel role for plasmin formed on dead cells and other phagocytic targets in maintaining tissue homeostasis by increasing the phagocytic function of dendritic cells while simultaneously decreasing their immunostimulatory capacity consistent with producing an immunosuppressive state.
Subject(s)
Dendritic Cells/physiology , Fibrinolysin/physiology , Immunity, Innate/physiology , Phagocytosis/physiology , Adaptive Immunity/physiology , Animals , Cells, Cultured , Flow Cytometry , Humans , Lymphocyte Activation/physiology , Male , Mice, Inbred C57BL , Recombinant Fusion Proteins , Transforming Growth Factor beta/physiologyABSTRACT
BACKGROUND: Many current vaccines to a specific pathogen influence responses to other pathogens in a process called heterologous immunity. We propose that their particulate nature contributes to non-specific effects. Herein, we demonstrate polystyrene nanoparticles modulate dendritic cell (DC) homeostasis, thereby promoting a persistent enhanced state of immune readiness to a subsequent infectious challenge. METHODS: Particles (approximately 40 nm and 500 nm carboxylated polystyrene nanoparticles; PSNPs) alone or conjugated to a model antigen were injected in mice, and DCs in draining lymph nodes (dLNs) and bone-marrow (BM) quantified by flow cytometry. BM cells were tested for capacity to generate DCs upon culture with granulocyte and macrophage colony stimulating factor. Mice were challenged with Plasmodium yoelli. Blood parasitaemias were monitored by GIEMSA. Sera was analyzed for antibodies by ELISA. RESULTS: Intradermal administration of 40 nm PSNPs induced anti-inflammatory cytokines, chemokines and growth factors, increased numbers and proportions of DCs in the dLN, and increased the capacity of BM to generate DCs. Consistent with these unexpected changes, 40 nm PSNPs pre-injected mice had enhanced ability to generate immunity to a subsequent malarial infection. CONCLUSIONS: Intradermal administration of 40 nm PSNPs modifies DC homeostasis, which may at least in part explain the observed beneficial heterologous effects of current particulate vaccines. Further nanotechnological developments may exploit such strategies to promote beneficial non-specific effects.
Subject(s)
Cytokines/drug effects , Dendritic Cells/drug effects , Malaria Vaccines/pharmacology , Malaria/immunology , Malaria/prevention & control , Nanoparticles , Signal Transduction/drug effects , Vaccines, Synthetic/pharmacology , Adjuvants, Immunologic/pharmacology , Animals , Cytokines/immunology , Dendritic Cells/immunology , Disease Models, Animal , Homeostasis , Immunoconjugates/pharmacology , Mice , Mice, Inbred C57BL , Nanoparticles/chemistry , Particle Size , Signal Transduction/immunologyABSTRACT
It has recently become clear that nanoparticle size is a major determinant for how antigen presenting cells (APCs), and specifically dendritic cells (DC) recognize and handle particles, and hence a critical parameter for the formulation of particulate vaccines that aim to induce immunity by targeting DC. Our previous studies in mice and sheep have shown polystyrene nanoparticles of 40-50 nm (PSNPs) with covalently bound antigen offer a new class of vaccines, which contain only 2 elements, antigen and particle, and no added inflammatory stimuli, but evoke very potent combined CD8 T cell and antibody responses. Herein we have optimized the methods for antigen conjugation to PSNPs to controllably promote a single antigen (protein or peptide) layer coating on the nanoparticle. Surprisingly, these nanovaccines not only continued to induce high levels of CD8 T cells in vivo, but were further more potent antibody inducers than nanoparticles containing multiple antigen layers. Addressing the issue of antigen loading on PSNPs, we found an optimal range, above or below which immunogenicity is changed either for antibodies or CD8 T cells. The mechanism behind the induction of high levels of CD8 T cells was further explored by assessing the DC subset that takes up the PSNPs in vivo, and these were found to be preferentially CD8(+) CD11c(+) DC in the lymph node draining the injection site. Since the levels of induced antibodies were highly elevated, and CD8(+) DC do not traditionally induce antibodies, we further sought to find if, despite no detectable inflammation at the injection site, the PSNPs may perhaps induce inflammatory cytokines locally in the lymph node after injection, or systemically in sera, resulting in an adjuvant effect. The initial findings presented herein show no detectable induction of the key inflammatory cytokines such as TNF-α, IL-1 or IL-6, suggesting a novel "non-inflammatory" adjuvant mechanism.
Subject(s)
Antigens/immunology , CD8-Positive T-Lymphocytes/drug effects , Dendritic Cells/drug effects , Immune System , Immunoconjugates/chemistry , Nanoparticles/chemistry , Polystyrenes/immunology , Vaccines, Synthetic/immunology , Adjuvants, Immunologic/chemistry , Animals , Antibodies/blood , CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/immunology , Cytokines/deficiency , Cytokines/immunology , Dendritic Cells/cytology , Dendritic Cells/immunology , Humans , Immunoconjugates/administration & dosage , Immunoconjugates/immunology , Mice , Particle Size , Polystyrenes/chemistry , Sheep , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/chemistryABSTRACT
Suppressor of cytokine signaling (SOCS)-1 is a critical inhibitor of IFN-gamma signal transduction in vivo, but the precise biochemical mechanism of action of SOCS-1 is unclear. Studies in vitro have shown that SOCS-1 binds to Jaks and inhibits their catalytic activity, but recent studies indicate SOCS-1 may act in a similar manner to SOCS-3 by firstly interacting with cytokine receptors and then inhibiting Jak activity. Here, we have generated mice, termed Ifngr1(441F), in which a putative SOCS-1 binding site, tyrosine 441 (Y441), on the IFN-gamma receptor subunit 1 (IFNGR1) is mutated. We confirm that SOCS-1 binds to IFNGR1 in wild-type but not mutant cells. Mutation of Y441 results in impaired negative regulation of IFN-gamma signaling. IFN-gamma-induced STAT1 activation is prolonged in Ifngr1(441F) cells, but not to the extent seen in cells completely lacking SOCS-1, suggesting that SOCS-1 maintains activity to modulate IFN-gamma signaling via other mechanisms. Despite this, we show that hypersensitivity to IFN-gamma results in enhanced innate tumor protection in Ifngr1(441F) mice in vivo, and unregulated expression of an IFN-gamma-dependent chemokine, monokine-induced by IFN-gamma. Collectively, these data indicate that Y441 contributes to the regulation of signaling through IFNGR1 via the recruitment of SOCS-1 to the receptor.
Subject(s)
Interferon-gamma/physiology , Protein Subunits/metabolism , Receptors, Interferon/metabolism , Signal Transduction/immunology , Suppressor of Cytokine Signaling Proteins/metabolism , Tyrosine/metabolism , Animals , Cells, Cultured , Gene Knock-In Techniques , Interferon-gamma/deficiency , Interferon-gamma/genetics , Lung Neoplasms/genetics , Lung Neoplasms/immunology , Lung Neoplasms/secondary , Melanoma, Experimental/genetics , Melanoma, Experimental/immunology , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Protein Binding/genetics , Protein Binding/immunology , Protein Subunits/deficiency , Protein Subunits/genetics , Receptors, Interferon/deficiency , Receptors, Interferon/genetics , Signal Transduction/genetics , Suppressor of Cytokine Signaling 1 Protein , Suppressor of Cytokine Signaling Proteins/deficiency , Suppressor of Cytokine Signaling Proteins/genetics , Tyrosine/genetics , Interferon gamma ReceptorABSTRACT
The noncanonical NF-kappaB pathway regulates the development and function of multiple organs and cell lineages. We have generated mice harboring a novel mutation in Nfkb2 that prevents the processing of the inhibitory precursor, p100, into the active subunit, p52. Mutant mice express a complex phenotype with abnormalities in a variety of tissues, and with a spectrum that is more severe than in mice carrying a targeted deletion of Nfkb2. Signaling through the noncanonical pathway is ablated due to the absence of p52, resulting in disorganized splenic architecture and disrupted B cell development. The inhibitory precursor form of NF-kappaB2 interacts with RelA, preventing activation of RelA dimers in response to both canonical and noncanonical stimuli, which in combination with p52 deficiency, results in defective lymph node formation and bone homeostasis. These findings demonstrate a key role for NF-kappaB2 in the regulation of RelA activation and suggest overlap in the function of NF-kappaB members in canonical and noncanonical pathway signaling.
Subject(s)
NF-kappa B p52 Subunit/physiology , Animals , B-Lymphocytes/immunology , Female , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mutation , NF-kappa B p52 Subunit/genetics , Osteoclasts/immunology , Pedigree , T-Lymphocytes/immunology , Transcription Factor RelA/physiologyABSTRACT
The capacity of mouse spleen conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs) to produce interferon-gamma (IFN-gamma) or IFN-alpha was assessed, and compared with that of natural killer (NK) cells and the recently identified interferon-producing killer dendritic cells (IKDCs), both of which are frequent contaminants in DC preparations. Fully developed cDCs or pDCs, if free of NK cells or IKDCs, showed little capacity for IFN-gamma production. However, an early developmental form of the CD4-8+ cDC subtype, and the Ly6C- Ly49Q- pDC subtype, both were able to produce moderate amounts of IFN-gamma, although less than IKDCs. In response to toll-like receptor 9 stimuli, both the Ly6C+ Ly49Q+ and the Ly6C- Ly49Q- pDC subtypes were effective producers of IFN-alpha. However, IKDCs, which efficiently produced IFN-gamma and showed immediate cytotoxicity on NK target cells, did not produce IFN-alpha under these conditions.
Subject(s)
Dendritic Cells/immunology , Interferons/biosynthesis , Killer Cells, Natural/immunology , Animals , Antigens, CD/analysis , Antigens, Ly/analysis , Cells, Cultured , Dendritic Cells/metabolism , Immunophenotyping , Interferon-alpha/biosynthesis , Interferon-gamma/biosynthesis , Killer Cells, Natural/metabolism , MiceABSTRACT
Four years after the discovery of mouse plasmacytoid dendritic cells (pDC), pDC are still very much an 'enigmatic' cell type. It is clear that pDC are potent producers of type I IFN in response to viral, bacterial and even mammalian nucleotides. The role that they play in vivo before and after activation is still under scrutiny. This review concentrates on the pathways to activation of pDC, examining the activating ligands, receptors and signalling molecules that are known to be involved, and the relevance of these activation pathways to human disease.
Subject(s)
Dendritic Cells/immunology , Dendritic Cells/metabolism , Receptors, Pattern Recognition/physiology , Animals , Dendritic Cells/microbiology , Dendritic Cells/virology , Humans , Ligands , Signal Transduction/immunologyABSTRACT
Botulinum neurotoxin C1 (BoNt C1) and its corresponding gene were detected in seven aquatic habitats covering a range of low (LR) to high risk (HR) avian botulism outbreak areas during a study period of 10 months. Toxin and gene in sediment and avian faecal samples were analysed before (in situ) and after cultivation (in vitro) by a newly adapted ELISA, the common mouse bioassay and by a recently described nested PCR protocol. BoNt C1 gene fragments were detected in 74% and 83% of all investigated sediment samples by in situ PCR and in vitro PCR, respectively, at comparable frequencies in HR and LR areas. Similar high values were also observed for faecal samples. No BoNt C1 could be detected in the sediment in situ, while 53% and 56% of all cultivated samples contained BoNt C1 as detected in the mouse bioassay and the ELISA, respectively. The percentage of BoNt C1 positive cultivated samples was significantly higher (2-fold) in HR areas than in LR areas. Hence, our data clearly indicate an increased ratio of potentially BoNt C1 producing clostridia to BoNt C1 genes as the frequency or likelihood of botulinum epizootics increases in the environment. In addition, the good correlation between the results from the ELISA and the mouse bioassay for all sediment and faecal samples (r=0.90, p<0.001, n=121) indicates a high potential for the ELISA to reduce/replace the mouse bioassay for the detection of BoNt C1 in environmental samples.
Subject(s)
Bird Diseases/virology , Botulinum Toxins/analysis , Botulinum Toxins/genetics , Botulism/veterinary , Animals , Birds , Disease Outbreaks/veterinary , Environment , Environmental Monitoring , Enzyme-Linked Immunosorbent Assay , Geologic Sediments/analysis , Mice , Polymerase Chain ReactionABSTRACT
Reticuloendotheliosis viral oncogene homolog/nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (Rel/NF-kappaB) activation is a ubiquitous outcome of engaging Toll-like receptors (TLRs), yet the cell-type-specific functions of this pathway in response to particular microbial signals remain poorly defined. Here we show that NF-kappaB1 and C-Rel, Rel/NF-kappaB proteins induced in conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs) by cytosine-phosphate-guanosine (CpG) DNA, a TLR-9 ligand, serve markedly different functions in these DC subsets. With the exception of impaired interleukin-12 (IL-12) production, cultured Nfkb1(-/-)C-Rel(-/-) cDCs responded relatively normally to CpG DNA. In contrast, CpG-treated Nfkb1(-/-)C-Rel(-/-) pDCs, which were still able to produce type I interferon and regulated on activation normal T-cell expressed and secreted (RANTES), but not IL-6 or IL-12, failed to acquire an activated dendritic phenotype and underwent apoptosis. Although the TLR-9-mediated death of Nfkb1(-/-)C-Rel(-/-) pDCs, which coincided with a failure to up-regulate the prosurvival proteins B-cell lymphoma apoptosis regulator xL (Bcl-x(L)) and A1, was blocked by Bcl-2 transgene expression, this inhibition of apoptosis still failed to rescue the differentiation defects. This indicated that these NF-kappaB transcription factors independently regulate TLR-9-mediated pDC morphogenesis and survival. Collectively, these findings establish that NF-kappaB1 and c-Rel, while largely dispensable for TLR-9-induced cDC activation, are critical for regulating differentiation and survival programs during pDC activation.
Subject(s)
Cell Differentiation/immunology , Dendritic Cells/immunology , NF-kappa B p50 Subunit/immunology , Plasma Cells/immunology , Proto-Oncogene Proteins c-rel/immunology , Signal Transduction/immunology , Toll-Like Receptor 9/immunology , Animals , Cell Death/drug effects , Cell Death/immunology , Cell Survival/drug effects , Cell Survival/immunology , Cells, Cultured , CpG Islands/immunology , Cytokines/biosynthesis , Cytokines/immunology , Dendritic Cells/cytology , Genes, bcl-2/genetics , Genes, bcl-2/immunology , Mice , Mice, Knockout , NF-kappa B p50 Subunit/genetics , Oligodeoxyribonucleotides/immunology , Oligodeoxyribonucleotides/pharmacology , Plasma Cells/cytology , Proto-Oncogene Proteins c-rel/genetics , Reticuloendotheliosis virus/immunology , Signal Transduction/drug effects , bcl-X Protein/genetics , bcl-X Protein/immunologyABSTRACT
We demonstrate that functional and phenotypic equivalents of mouse splenic CD8(+) and CD8(-) conventional dendritic cell (cDC) subsets can be generated in vitro when bone marrow is cultured with fms-like tyrosine kinase 3 (flt3) ligand. In addition to CD45RA(high) plasmacytoid DC, two distinct CD24(high) and CD11b(high) cDC subsets were present, and these subsets showed equivalent properties to splenic CD8(+) and CD8(-) cDC, respectively, in the following: 1) surface expression of CD11b, CD24, and signal regulatory protein-alpha; 2) developmental dependence on, and mRNA expression of, IFN regulatory factor-8; 3) mRNA expression of TLRs and chemokine receptors; 4) production of IL-12 p40/70, IFN-alpha, MIP-1alpha, and RANTES in response to TLR ligands; 5) expression of cystatin C; and 6) cross-presentation of exogenous Ag to CD8 T cells. Furthermore, despite lacking surface CD8 expression, the CD24(high) subset contained CD8 mRNA and up-regulated surface expression when transferred into mice. This culture system allows access to bona fide counterparts of the splenic DC subsets.
Subject(s)
Bone Marrow Cells/immunology , CD8 Antigens/biosynthesis , Cell Differentiation/immunology , Dendritic Cells/cytology , Dendritic Cells/immunology , Membrane Proteins/metabolism , Proto-Oncogene Proteins/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Spleen/immunology , Animals , Antigen Presentation/genetics , Antigen Presentation/immunology , Bone Marrow Cells/cytology , Bone Marrow Cells/metabolism , CD4 Antigens/biosynthesis , CD4 Antigens/genetics , CD8 Antigens/genetics , Cell Differentiation/genetics , Cells, Cultured , Chemokines/biosynthesis , Cross-Priming/genetics , Cross-Priming/immunology , Cystatin C , Cystatins/biosynthesis , Cytokines/biosynthesis , Dendritic Cells/metabolism , Immunophenotyping , Interferon Regulatory Factors , Ligands , Membrane Glycoproteins/biosynthesis , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Receptors, Cell Surface/biosynthesis , Receptors, Chemokine/biosynthesis , Repressor Proteins/biosynthesis , Repressor Proteins/genetics , Repressor Proteins/physiology , Spleen/cytology , Spleen/metabolism , Toll-Like Receptors , fms-Like Tyrosine Kinase 3ABSTRACT
A laboratory accident resulted in human exposure to a recombinant raccoon poxvirus (RCN) developed as a vaccine vector for antigens of Yersinia pestis for protection of wild rodents (and other animals) against plague. Within 9 days, the patient developed a small blister that healed within 4 weeks. Raccoon poxvirus was cultured from the lesion, and the patient developed antibody to plague antigen (F1) and RCN. This is the first documented case of human exposure to RCN.